ubenimex has been researched along with aclarubicin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kurita, S; Masaoka, T; Ogawa, N; Ota, K; Uzuka, Y; Yamada, K | 1 |
| Ishizuka, M | 1 |
| Chiba, H; Hirayama, Y; Matsunaga, T; Niitsu, Y; Sagawa, T; Sakamaki, S; Takayanagi, N; Tsuji, Y | 1 |
1 trial(s) available for ubenimex and aclarubicin
| Article | Year |
|---|---|
[Results of follow-up studies on prognosis after immunotherapy with bestatin in acute nonlymphocytic leukemia].
Topics: Aclarubicin; Acute Disease; Adjuvants, Immunologic; Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Follow-Up Studies; Humans; Leucine; Leukemia; Mercaptopurine; Middle Aged; Naphthacenes; Prednisolone; Prognosis; Random Allocation | 1986 |
2 other study(ies) available for ubenimex and aclarubicin
| Article | Year |
|---|---|
[Low molecular weight immunomodulators produced by microorganisms].
Topics: Aclarubicin; Adjuvants, Immunologic; Animals; Antibiotics, Antineoplastic; Concanavalin A; Glycine; Leucine; Lymphocyte Activation; Mice; Molecular Weight; Naphthacenes; Neoplasms, Experimental; Ribonucleosides | 1984 |
[Chemotherapy with ubenimex corresponding to patient age and organ disorder for 18 cases of acute myelogeneous leukemia in elderly patients--effects, complications and long-term survival].
Topics: Aclarubicin; Age Factors; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leucine; Leukemia, Myeloid, Acute; Male; Remission Induction; Survival Rate | 2003 |